UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

   Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange
                                   Act of 1934


       Date of Report (Date of earliest event reported) December 21, 2005


                         Calypte Biomedical Corporation
               (Exact name of Company as specified in its charter)

<TABLE>
<CAPTION>
<S>                             <C>                        <C>
Delaware                        000-20985                            06-1226727
--------                        ---------                            ----------
(State or Other Jurisdiction)   (Commission File Number)   (I.R.S. Employer Identification)
of Incorporation)
</TABLE>


             5 Centerpointe Drive, Suite 400, Lake Oswego, OR 97035
             ------------------------------------------------------
               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (971) 204-0282
                                                           --------------


                                       N/A
          -------------------------------------------------------------
          (Former name or former address, if changed since last report)

|_|   Written communication pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 40.13e-4(c))


<PAGE>

ITEM 1.01  ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT


(a)   On December 21,  2005,  the  Registrant  (the  "Company")  entered into an
Equity Transfer Agreement dated December 21, 2006, (the "Agreement") between the
Company and Marr Technologies Asia Limited ("Marr Technologies Asia"), a company
existing  under the laws of the  Republic of  Seychelles,  pursuant to which the
Company  acquired from Marr  Technologies  Asia a 51% equity interest in Beijing
Marr  Bio-Pharmaceutical  Co., Ltd.("Beijing  Marr"), a wholly  foreign-owned
enterprise  ("WFOE")  existing under the laws of the People's  Republic of China
("China").  Marr Technologies Asia is an affiliate of Marr  Technologies,  B.V.,
the Company's largest stockholder. The Agreement became effective on January 18,
2006, the date it was approved by the Huairou County Commerce  Bureau.  Pursuant
to the Agreement,  Marr  Technologies Asia will contribute USD $1,764,000 to the
registered  capital  of  Beijing  Marr  and  the  Company  will  contribute  USD
$1,836,000  to the  registered  capital  of  Beijing  Marr.  To  date,  Marr has
contributed  USD  $882,000 and the Company has  contributed  USD  $918,000.  The
remaining  capital   contributions   must  be  made  by  the  Company  and  Marr
Technologies  Asia in proportion to their respective equity interests in Beijing
Marr before November 17, 2006.

The Company  also  entered  into an  agreement  with Marr  Technologies  Asia in
connection  with the  Equity  Transfer  Agreement,  governing  the  relationship
between the Company and Marr Technologies Asia, as shareholders of Beijing Marr,
which provides for certain protective  provisions for Marr Technologies Asia, as
the   minority   shareholder,    board   composition   and   voting,   buy-sell,
non-competition  and other rights,  duties and  obligations of the  shareholders
(the "Shareholders Agreement") in connection with the operation of Beijing Marr.
The business purpose of Beijing Marr is to pursue the manufacture, distribution,
marketing and sale of the Company's products in China.

ITEM 7.01  REGULATION FD DISCLOSURE

      Beijing Marr entered into an Assets Transfer  Contract dated September 16,
2005 (the  "Contract")  between  Beijing Marr and Beijing Yaohua  Bio-Technology
Ltd., a limited liability company existing under the laws of China,  pursuant to
which  Beijing  Marr agreed to acquire  from Yaohua the assets of its  business,
which include the  Pharmaceutical  Manufacturing  Permit and Good  Manufacturing
Practices (GMP) certificate and approval numbers, manufacturing facilities, land
use rights,  tangible  assets  necessary  for  obtaining  and  maintaining a GMP
certification,   technology  and  other  assets  necessary  to  manufacture  and
distribute diagnostic test products in China (collectively, the "Assets").


ITEM 9.01  FINANCIAL STATMENTS AND EXHIBITS.

(d)   Exhibits.

   Exhibit No.      Description
-----------------   ------------------------------------------------------------
      10.168        Equity Transfer Agreement dated December 21, 2005 between
                    the Company and Marr Technologies Asia Limited
      10.169        Agreement  dated  December  21, 2005 between the Company and
                    Marr Technologies Asia Limited
       99.1         Press Release dated March 30, 2006



                                   SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:    March 30, 2006

                                    Calypte Biomedical Corporation

                                    By: /s/ Theodore R. Gwin
                                        -------------------------------------
                                        Theodore R. Gwin
                                        Chief Financial Officer
{"company-data": {"conformed-name": "CALYPTE BIOMEDICAL CORP", "cik": "0000899426", "assigned-sic": "3826", "irs-number": "061226727", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-32280", "film-number": "06722865"}, "business-address": {"street1": "5000 HOPYARD ROAD, SUITE 480", "city": "PLEASANTON", "state": "CA", "zip": "94588", "phone": "9257307200"}, "mail-address": {"street1": "5000 HOPYARD ROAD, SUITE 480", "city": "PLEASANTON", "state": "CA", "zip": "94588"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

   Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange
                                   Act of 1934

       Date of Report (Date of earliest event reported) December 21, 2005

                         Calypte Biomedical Corporation
               (Exact name of Company as specified in its charter)
Delaware                        000-20985                            06-1226727
--------                        ---------                            ----------
(State or Other Jurisdiction)   (Commission File Number)   (I.R.S. Employer Identification)
of Incorporation)
5 Centerpointe Drive, Suite 400, Lake Oswego, OR 97035
             ------------------------------------------------------
               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (971) 204-0282
                                                           --------------

                                       N/A
          -------------------------------------------------------------
          (Former name or former address, if changed since last report)

|_|   Written communication pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 40.13e-4(c))
ITEM 1.01  ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

(a)   On December 21,  2005,  the  Registrant  (the  "Company")  entered into an
Equity Transfer Agreement dated December 21, 2006, (the "Agreement") between the
Company and Marr Technologies Asia Limited ("Marr Technologies Asia"), a company
existing  under the laws of the  Republic of  Seychelles,  pursuant to which the
Company  acquired from Marr  Technologies  Asia a 51% equity interest in Beijing
Marr  Bio-Pharmaceutical  Co., Ltd.("Beijing  Marr"), a wholly  foreign-owned
enterprise  ("WFOE")  existing under the laws of the People's  Republic of China
("China").  Marr Technologies Asia is an affiliate of Marr  Technologies,  B.V.,
the Company's largest stockholder. The Agreement became effective on January 18,
2006, the date it was approved by the Huairou County Commerce  Bureau.  Pursuant
to the Agreement,  Marr  Technologies Asia will contribute USD $1,764,000 to the
registered  capital  of  Beijing  Marr  and  the  Company  will  contribute  USD
$1,836,000  to the  registered  capital  of  Beijing  Marr.  To  date,  Marr has
contributed  USD  $882,000 and the Company has  contributed  USD  $918,000.  The
remaining  capital   contributions   must  be  made  by  the  Company  and  Marr
Technologies  Asia in proportion to their respective equity interests in Beijing
Marr before November 17, 2006.

The Company  also  entered  into an  agreement  with Marr  Technologies  Asia in
connection  with the  Equity  Transfer  Agreement,  governing  the  relationship
between the Company and Marr Technologies Asia, as shareholders of Beijing Marr,
which provides for certain protective  provisions for Marr Technologies Asia, as
the   minority   shareholder,    board   composition   and   voting,   buy-sell,
non-competition  and other rights,  duties and  obligations of the  shareholders
(the "Shareholders Agreement") in connection with the operation of Beijing Marr.
The business purpose of Beijing Marr is to pursue the manufacture, distribution,
marketing and sale of the Company's products in China.

ITEM 7.01  REGULATION FD DISCLOSURE

      Beijing Marr entered into an Assets Transfer  Contract dated September 16,
2005 (the  "Contract")  between  Beijing Marr and Beijing Yaohua  Bio-Technology
Ltd., a limited liability company existing under the laws of China,  pursuant to
which  Beijing  Marr agreed to acquire  from Yaohua the assets of its  business,
which include the  Pharmaceutical  Manufacturing  Permit and Good  Manufacturing
Practices (GMP) certificate and approval numbers, manufacturing facilities, land
use rights,  tangible  assets  necessary  for  obtaining  and  maintaining a GMP
certification,   technology  and  other  assets  necessary  to  manufacture  and
distribute diagnostic test products in China (collectively, the "Assets").

ITEM 9.01  FINANCIAL STATMENTS AND EXHIBITS.

(d)   Exhibits.

   Exhibit No.      Description
-----------------   ------------------------------------------------------------
      10.168        Equity Transfer Agreement dated December 21, 2005 between
                    the Company and Marr Technologies Asia Limited
      10.169        Agreement  dated  December  21, 2005 between the Company and
                    Marr Technologies Asia Limited
       99.1         Press Release dated March 30, 2006

                                   SIGNATURES

Pursuant to the requirement of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:    March 30, 2006

                                    Calypte Biomedical Corporation

                                    By: /s/ Theodore R. Gwin
                                        -------------------------------------
                                        Theodore R. Gwin
                                        Chief Financial Officer